ZYM-51

ZYM-51 is a small molecule inhibitor of the interaction between the deubiquitinating enzyme USP5 and the Cav3.2 T-type calcium channel, developed by Zymedyne for the treatment of chronic and neuropathic pain. In chronic pain states, USP5 is pathologically upregulated and binds to Cav3.2 channels, preventing their proteasomal degradation and leading to increased channel expression and enhanced pain signaling. ZYM-51 selectively disrupts this USP5-Cav3.2 interaction, promoting the degradation of Cav3.2 channels and providing robust analgesia. This targeted approach selectively addresses aberrantly upregulated channels while sparing normal channel function, offering a non-opioid, non-addictive alternative for pain management with a reduced risk of side effects.